When was Neogene Therapeutics founded?

Neogene Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is Neogene Therapeutics located?

Neogene Therapeutics is headquartered in New York City, United States.

Who is the current CEO of Neogene Therapeutics?

Carsten Linnemann of Neogene Therapeutics. They have also founded 1 company.

How many employees does Neogene Therapeutics have?

As of Mar 31, 2026, the latest employee count at Neogene Therapeutics is 52.

Is Neogene Therapeutics a funded company?

Neogene Therapeutics is a funded company, having raised a total of $125M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 10, 2019.

When was the latest funding round of Neogene Therapeutics?

Neogene Therapeutics' latest funding was a $***** Series A round on Sep 02, 2020, with participation from 8 investors. Its primary sector is Oncology. In United States, the Oncology sector has seen $4.18B in funding in 2026 to date.

Where does Neogene Therapeutics rank among its competitors?

Neogene Therapeutics ranks 244th amongst 3362 active competitors, of which 1125 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Neogene Therapeutics?

Neogene Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Neogene Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Neogene Therapeutics is an acquired company based in New York City (United States), founded in 2018 by Carsten Linnemann. It operates as a Developer of T-cell therapy for treating cancer. Neogene Therapeutics has raised $125M in funding from investors like TPG, Two River and EcoR1. The company has 3362 active competitors, including 1125 funded and 782 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Neogene develops T-cell therapy for treating cancer. The company provides cancer patients with T cell therapies targeting mutated proteins called neo-antigens, which are present on cancer cells as a consequence of DNA mutations.

Website: neogene.com
Email ID: *****@neogene.com

Key Metrics

Founded Year

2018

Location

New York City, United States

Stage

Acquired

Total Funding

$125M in 2 rounds

Latest Funding Round

Series A, Sep 02, 2020, $*****

Investors

TPG & 9 more

Ranked

244^th among 3362 active competitors

Employee Count

52 as on Mar 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3004 more

Exit Details

Acquired by AstraZeneca (Nov 29, 2022)

View Neogene Therapeutics' full profile

Neogene Therapeutics got acquired by AstraZeneca on Nov 29, 2022.

Click here to take a look at Neogene Therapeutics's acquisition in detail

Neogene Therapeutics has raised a total funding of $125M over 2 rounds. Its first funding round was on May 10, 2019. Its latest funding round was a Series A round on Sep 02, 2020 for $*****. 8 investors participated in its latest round. Neogene Therapeutics has 10 institutional investors.

Here is the list of recent funding rounds of Neogene Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 02, 2020	1821463	Series A	1403355	9495173	5974506	1634557
May 10, 2019	1154855	Seed	9017780	5832599	Vida Ventures & 2 more	7630058

Access funding benchmarks and valuations. Sign up today!

View details of Neogene Therapeutics's funding rounds and investors

The founders of Neogene Therapeutics is Carsten Linnemann. Carsten Linnemann is the CEO of Neogene Therapeutics.

Here are the details of Neogene Therapeutics' key team members:

Carsten Linnemann: Co-Founder & CEO of Neogene Therapeutics.

View details of Neogene Therapeutics's Founder profiles and Board Members

Neogene Therapeutics' employee count trend

Neogene Therapeutics has 52 employees as of Mar 26. Here is Neogene Therapeutics's employee count trend over the years:

Employee count trend for Neogene Therapeutics

Uncover Neogene Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Neogene Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Neogene Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
244th	Neogene Therapeutics 2018, New York City (United States), Acquired	Developer of T-cell therapy for treating cancer	$125M	Sonostar Ventures, Syncona & 8 others	58/100